The Advancing Safe Medications for Moms and Babies Act of 2026 aims to increase medical research involving pregnant and lactating women so doctors have better information about how drugs affect these populations and their infants. The bill requires the FDA to update its regulations within 180 days to align with existing HHS protections for pregnant women in clinical trials, making it easier for them to safely participate in drug studies. It also directs the Department of Health and Human Services to launch a public education campaign with $5 million annually through fiscal year 2031 to inform patients, families, and healthcare providers about available clinical trials and registries that include pregnant and lactating women. Additionally, the bill establishes a research prioritization process at the National Institutes of Health to fund studies on existing and new drugs used by pregnant and lactating women, with reporting requirements to Congress over a five-year period. The legislation addresses a significant gap in medical knowledge by ensuring that pregnant and nursing mothers can safely contribute to clinical research that will ultimately improve treatment options for their own health and their babies' health.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.